You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

~ Buy the ANORO ELLIPTA (umeclidinium bromide; vilanterol trifenatate) Drug Profile, 2024 PDF Report in the Report Store ~

Bulk Pharmaceutical API Sources for ANORO ELLIPTA

✉ Email this page to a colleague

« Back to Dashboard

Bulk Pharmaceutical API Sources for ANORO ELLIPTA

Subscribe to access the full database, or Try a Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE	⤷ Try a Trial	HY-12100	⤷ Try a Trial
AbaChemScene	⤷ Try a Trial	CS-0874	⤷ Try a Trial
Vesino Industrial Co., Ltd	⤷ Try a Trial	VA12030	⤷ Try a Trial
Lancrix Chemicals	⤷ Try a Trial	283443	⤷ Try a Trial
Race Chemical	⤷ Try a Trial	RV022509873	⤷ Try a Trial
Ark Pharm, Inc.	⤷ Try a Trial	AK174796	⤷ Try a Trial
AKos Consulting & Solutions	⤷ Try a Trial	AKOS025404842	⤷ Try a Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.